Articles From: Data from EPIRUS’ Phase 3 Study of BOW015, a biosimilar infliximab, to be Presented as a Late Breaking Poster at the American College of Rheumatology Annual Meeting to Datawatch Schedules First Quarter of Fiscal Year 2015 Conference Call and Earnings Release


2014/11/17
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today announced they will present data from their Phase 3 study, "BOW015, a Biosimilar Infliximab, in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses: 54-Week Results of a Randomized, Double-Blind, Active Comparator Study,” at the 2014 Annual Scientific Meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals (ACR/ARHP), November 18, in Boston, MA.
Sign-up for Data from EPIRUS’ Phase 3 Study of BOW015, a biosimilar infliximab, to be Presented as a Late Breaking Poster at the American College of Rheumatology Annual Meeting investment picks
Celgene Corporation (NASDAQ:CELG) today announced that data from more than 160 abstracts, including 39 oral presentations, evaluating Celgene investigational products and investigational uses of marketed products will be presented at the 56 th American Society of Hematology Annual Meeting between Dec.
Sign-up for Data from More Than 160 Abstracts Highlighting Celgene Therapies to Be Presented at American Society of Hematology Annual Meeting (ASH) investment picks
95% (19/20) Overall Response Rate (ORR) in Patients with High-Risk CLL, the patient population to be studied in recently announced Phase 3 Clinical Trial being conducted under Special Protocol Assessment (SPA) 87% (34/39) ORR per iwCLL criteria in all evaluable CLL patients plus an additional 10% of patients with a nodal PR or nodal reductions ranging from 20%-45% without disease progression 88% (7/8) ORR in all evaluable Mantle Cell Lymphoma (MCL) patients with a 38% (3/8) Complete Response rate Combination of TG-1101 + Ibrutinib well tolerated with limited Grade 3/4 events reported to date SAN FRANCISCO, Dec.
Sign-up for Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical Activity in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) investment picks
http://media.marketwire.com/attachments/201004/586398_dataiologo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1162170&ProfileId=051205&sourceType=1 REDMOND, WA --
Sign-up for Data I/O Engages SM Berger & Company as Investor Relations Firm investment picks
http://media.marketwire.com/attachments/201004/586398_dataiologo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1155302&ProfileId=051205&sourceType=1 REDMOND, WA --
Sign-up for Data I/O Reports Third Quarter 2014 Results investment picks
http://media.marketwire.com/attachments/201004/586398_dataiologo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1160100&ProfileId=051205&sourceType=1 REDMOND, WA --
Sign-up for Data I/O to Present at LD Micro Conference on December 3rd investment picks
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating an overall response rate of 18.5 percent with KEYTRUDA, the company’s anti-PD-1 therapy, as assessed by RECIST v1.1, central review (n=5/27), in PD-L1 positive, advanced triple-negative breast cancer – one of the most aggressive forms of breast cancer.
Sign-up for Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breast Cancer Presented at 2014 San Antonio Breast Cancer Symposium investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating that KEYTRUDA ® (pembrolizumab), the company’s anti-PD-1 therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82), in transplant-ineligible and failure patients with relapsed/refractory classical Hodgkin Lymphoma (cHL) whose disease progressed on or after treatment with brentuximab vedotin.
Sign-up for Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting investment picks
http://media.marketwire.com/attachments/201207/48976_Astellas_logo.jpg http://media.marketwire.com/attachments/201203/41309_medivation_logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1164742&ProfileId=051205&sourceType=1 SAN FRANCISCO, CA and TOKYO, JAPAN --
Sign-up for Data Presented From Phase 2 Study of Enzalutamide in Advanced Androgen-Receptor Positive, Triple-Negative Breast Cancer investment picks
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced a retrospective data analysis from the CHAMPION clinical trial showing significant a reduction in 30-day hospital readmission rates for patients age 65 and older.
Sign-up for Data Shows the CardioMEMS HF System Significantly Reduced 30-Day Hospital Readmission Rates investment picks
http://media.marketwire.com/attachments/201404/243780_Peregrine_logo_CMYK_sanspharm.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1164678&ProfileId=051205&sourceType=1 TUSTIN, CA --
Sign-up for Data to Be Presented at 2014 San Antonio Breast Cancer Symposium Demonstrate Immune-Stimulatory Properties of Peregrine Pharmaceuticals' Bavituximab in Models of Breast Cancer investment picks
Datalink (Nasdaq: DTLK), a leading provider of data center infrastructure and services, today announced that Paul Lidsky, president and CEO, and Greg Barnum, chief financial officer, are scheduled to present at the following investor conferences: About Datalink A complete data center solutions and services provider for Fortune 500 and mid-tier enterprises, Datalink transforms data centers so they become more efficient, manageable and responsive to changing business needs.
Sign-up for Datalink Announces Upcoming Investor Conferences investment picks
Datalink (Nasdaq: DTLK), a leading provider of data center infrastructure and services, today announced that Paul Lidsky, president and CEO, and Greg Barnum, chief financial officer, are scheduled to present at the following investor conferences: About Datalink A complete data center solutions and services provider for Fortune 500 and mid-tier enterprises, Datalink transforms data centers so they become more efficient, manageable and responsive to changing business needs.
Sign-up for Datalink Announces Upcoming Investor Conferences investment picks
Datalink (NASDAQ: DTLK), a leading provider of data center infrastructure and services, today announced the successful completion of a data storage and disaster recovery infrastructure upgrade project for the City of Riverside, California.
Sign-up for Datalink Upgrades City of Riverside’s Storage & Disaster Recovery Infrastructure investment picks
2015/1/5
LiveRamp, an Acxiom company, and Datalogix today announced an expansion of their partnership, which now runs through the end of 2017.
Sign-up for Datalogix and LiveRamp, an Acxiom Company, Sign Multi-Year Agreement investment picks
2014/11/18
On November 17, 2014, Dataram Corporation (the “Company”; NASDAQ:DRAM) and certain institutional investors, including Isaac Capital Group, as lead investor, closed a securities purchase agreement (the “Purchase Agreement”), pursuant to which the Company agreed to sell up to an aggregate of 1,300,000 shares of its Series A Preferred Stock (the “Series A Stock”), together with warrants to purchase shares of common stock, to such investors at a price of $5.00 per share (the “Preferred Stock Transaction”). The sale of the Series A Stock will take place in multiple tranches.
Sign-up for Dataram Announces Sale of up to $6.5 Million of Series A Preferred Stock, Election of New Directors and Other Results of Shareholders’ Meeting investment picks
2014/12/3
On December 3, 2014, Dataram Corporation (the “Company”) announced that on December 2, 2014, the Company was notified by the NASDAQ Stock Market, LLC that, based upon the Company’s submission of the appropriate documentation, the Company has demonstrated compliance with the minimum $2,500,000 stockholders’ equity requirement for continued listing on The NASDAQ Capital Market.
Sign-up for Dataram Regains Compliance for Continued Listing on NASDAQ investment picks
Dataram Corporation (NASDAQ:DRAM) reported its financial results for its three and six months ended October 31, 2014.
Sign-up for Dataram Reports Fiscal 2015 Second Quarter and Year to Date Financial Results investment picks
2014/12/3
CHELMSFORD, Mass.
Sign-up for Datawatch Among Database Trends and Applications Trend-Setting Products for 2015 investment picks
2014/11/19
CHELMSFORD, Mass.
Sign-up for Datawatch Announces Fiscal Fourth Quarter 2014 Financial Results investment picks
2015/1/13
CHELMSFORD, Mass.
Sign-up for Datawatch Announces Preliminary First Quarter 2015 Financial Results investment picks
2014/11/10
Will be joined by executives from MasterCard, AIG, Spiderbook CHELMSFORD, Mass.
Sign-up for Datawatch CEO to Lead Panel on Data Monetization at Upcoming CDO Executive Forum 2014 investment picks
2014/10/23
University of Montana and UCLA researchers to discuss groundbreaking projects CHELMSFORD, Mass.
Sign-up for Datawatch Customers to Reveal Clinical Treatment Potential of Real-Time Visualizations at IBM Insight investment picks
2014/11/25
Fun interactive demo shows source of most holiday calories CHELMSFORD, Mass.
Sign-up for Datawatch Helps Separate Thanksgiving Fat From Lean with Data Visualization investment picks
2014/11/6
CHELMSFORD, Mass.
Sign-up for Datawatch Partners with Xerox to Accelerate Clients' Migration to Digital investment picks
2014/11/10
CHELMSFORD, Mass.
Sign-up for Datawatch Recognized Second Year in a Row as Best Big Data Technology Provider to the Buy-Side investment picks
2015/1/15
CHELMSFORD, Mass.
Sign-up for Datawatch Schedules First Quarter of Fiscal Year 2015 Conference Call and Earnings Release investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Data from EPIRUS’ Phase 3 Study of BOW015, a biosimilar infliximab, to be Presented as a Late Breaking Poster at the American College of Rheumatology Annual Meeting to Datawatch Schedules First Quarter of Fiscal Year 2015 Conference Call and Earnings Release
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent